TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Indapta Therapeutics announces the initiation of patient treatments with IDP-023 Allogeneic Natural Killer (NK) Cell Therapy for Cancer

Friday, January 12, 2024

Indapta Therapeutics, a privately held biotechnology firm specializing in the development of IDP-023, a natural killer (NK) cell therapy for cancer treatment, has initiated its Phase 1 clinical trial for multiple myeloma and Non-Hodgkin’s lymphoma. The University of Texas MD Anderson Cancer Center and NEXT Oncology, Virginia, treated the initial patients.

The first patient received a single dose of IDP-023, and the second patient underwent the initial of three planned doses. Subsequent patient groups will receive three doses of IDP-023 with or without interleukin-2. Following the establishment of safety with multiple doses in combination with interleukin-2, patients with lymphoma and multiple myeloma will be treated with IDP-023 in conjunction with rituximab and daratumumab monoclonal antibodies, respectively.

Dr. Mark Frohlich, CEO of Indapta, expressed enthusiasm about transitioning to a clinical stage company and highlighted the superior activity of IDP-023 compared to conventional NK cells in preclinical models. The company has successfully manufactured enough IDP-023 to sustain the Phase 1 clinical trial until the second half of 2024, achieving high yields in its GMP production runs.

Indapta's allogeneic NK cell therapy platform features "G minus" NK cells, or "g-NK," which enhance the cancer-killing capabilities of monoclonal antibody therapy without genetic engineering. IDP-023 is generated by selectively expanding g-NK cells from healthy donors with increased numbers of these cells. The cryopreserved g-NK cell therapy stands out for its low variability.

In preclinical studies, IDP-023 has exhibited more potent and durable antitumor activity when combined with cancer-targeting monoclonal antibodies compared to conventional NK cells, releasing significantly more immune-activating cytokines and cancer-killing compounds (Bigley et al., Blood Advances 2020, https://doi.org/10.1182/bloodadvances.2020002440). Frohlich is optimistic about the competitive cost of goods at the time of product launch due to recent improvements in the manufacturing process and planned changes.

 

Source: businesswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit